On March 28, 2026, the "2026 Greater Bay Area Immune Metabolism and Innovative Cancer Therapy Conference & Shenzhen International Cancer and Health Conference" was held at the Shenzhen Capital Group Academy. Co-organized by the China Association for the Care of the Elderly, the Shenzhen Food Industry Association, and the Shenzhen Anti-Cancer Association, and co-sponsored by The Eighth Affiliated Hospital of Sun Yat-sen University and the Shenzhen Tianyou Medical Research Institute, the conference focused on frontier directions in immune metabolism and cancer therapy. Through expert presentations, roundtable forums, and case studies, it established a high-level, cross-disciplinary platform for academic exchange and industrial collaboration.

During the conference, Shi Yuanyuan, Professor and Chairman of Shenzhen Cell Valley Group, was invited to attend and deliver a special report titled "Research Progress of Novel CAR-NK Cell Therapy for Solid Tumors" at the main forum of the "Shenzhen International Cancer and Health Conference." Professor Shi systematically shared the latest advancements in CAR-NK cell therapy regarding safety, accessibility, standardized manufacturing, and clinical translation, addressing long-standing bottlenecks in solid tumor treatment. He highlighted the exploration achievements of novel CAR-NK technologies in enhancing tumor killing efficiency, improving adaptability to the tumor microenvironment, and facilitating clinical application. As a major frontier in cell therapy, CAR-NK is becoming a highly anticipated new force in the solid tumor immunotherapy arena, distinguished by its characteristics of being "safer, more accessible, more universal, and better suited for industrialization."

Professor Shi Yuanyuan stated that solid tumors remain one of the most challenging yet breakthrough-worthy directions in the field of cell therapy. With the continuous improvement of cell engineering, vector delivery, manufacturing processes, and clinical translation systems, a new generation of cell therapy technologies represented by CAR-NK is accelerating from laboratory research to clinical application, promising to provide new treatment options and hope for a wider range of solid tumor patients.

As a key driver of industrialization and clinical translation in cell and gene therapy, Cell Valley Group has long focused on cell therapy, viral vectors, exosomes, and the clinical translation of new biomedical technologies, continuously building a one-stop platform system covering R&D, manufacturing, quality control, translation, and delivery. Professor Shi's keynote presentation at the main forum not only reflects Shenzhen Cell Valley's technical accumulation and industry influence in frontier cell therapy fields like CAR-NK but also further demonstrates the company's responsibility and commitment to deeply participating in medical technology innovation in the Greater Bay Area and serving the development of precision cancer therapy.

In the future, Shenzhen Cell Valley will continue to adhere to a clinical demand-oriented approach and technology-driven innovation. Focusing on major disease areas such as solid tumors, the company will continue to increase R&D and translation investment, promoting more original, breakthrough, and implementable cell therapy technologies toward clinical application to serve patients, contributing greater strength to the innovative development of cancer treatment in China and the high-quality development of the life and health industry in the Greater Bay Area.